Collaboration and Licensing Agreements - Narrative (Details) $ in Thousands, $ in Millions, ¥ in Billions	1 Months Ended			3 Months Ended			77 Months Ended
	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2024 CAD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2024 JPY (¥)	Oct. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Apr. 30, 2022 USD ($) payment_tranche	Mar. 31, 2018 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 46,023		$ 11,369
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				17		12
Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				368		0
Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				2,126		2
2017 KKC Agreement | Non-cash royalty revenue related to the sale of future royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				400
2017 KKC Agreement | Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				2,100		2
Fosun Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				0		0
Knight Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				0		0
KKC | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees		$ 30,000
Potential development milestones		$ 55,000
Total revenues							$ 35,000
Potential commercialization milestones				56,200			56,200	¥ 8.5
Fee receivable for reduction in royalty rate													$ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche													2
KKC | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments										$ 30,000		$ 35,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments				8,000			8,000		$ 3,000		$ 2,000
Upfront payment received	$ 12,000
Potential development and commercialization milestones				$ 113,000
Threshold percentage of net sales for tiered royalties				20.00%	20.00%
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones				$ 700			700
Non-cash royalty revenue														$ 2,300
Potential development and commercialization milestones				16,300	$ 22.2
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue			10.00%
Percentage of non-royalty revenue			20.00%
Maximum potential payment per agreement			$ 75,000
Aggregate cost of revenue recognized				32,400			$ 32,400
Cost of revenue				$ 4,700		$ 1,200